

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/049604 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/16 (2006.01)
A61K 31/4045 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/044223

(22) International Filing Date:

28 August 2024 (28.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/535,282 29 August 2023 (29.08.2023) US
63/572,752 01 April 2024 (01.04.2024) US

(71) Applicant: **MAZE THERAPEUTICS, INC.** [US/US];
171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(72) Inventors: **PITZEN, Jennifer**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **ZIEBENHAUS, Chris**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **MELLEM, Kevin**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **COOPER, Nicole**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **REID, Adam Neil**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **SCHAMMEL, Alexander Wayne**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **KARMEL, Caleb Henry**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **SINZ, Christopher Joseph**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **LEE, Patrick Sang Tae**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **WAHLERS, Jessica**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **FASTMAN, Nathan**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San

Francisco, California 94080 (US). **TZITZILONIS, Christos**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **MORGANS, David, John, Jr.**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **LIU, Yuxi**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(74) Agent: **MCBRIAR, Mark, D.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF



(57) Abstract: Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, R¹, R², R³, R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I). Also provided herein are methods of inhibiting SLC6A19 and methods of treating a SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.

WO 2025/049604 A1